Drug
Ismigen
Ismigen is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
20%
Ph phase_3
4
80%
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Phase Distribution5 total trials
Phase 3Large-scale testing
4(80.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 34 (80.0%)
Phase 41 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Effect of Bacterial Lysate on Nasal Carriage of Staphylococcus Aureus
NCT04637425
completedphase_3
The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells
NCT04802616
completedphase_3
Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis
NCT04270552
completedphase_3
Efficacy Of Bacterial Lysate In Asthmatic Children
NCT02541331
completedphase_4
Advanced Immunological Approach in COPD Exacerbation
NCT02417649
Clinical Trials (5)
Showing 5 of 5 trials
NCT04637425Phase 3
Effect of Bacterial Lysate on Nasal Carriage of Staphylococcus Aureus
NCT04802616Phase 3
The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells
NCT04270552Phase 3
Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis
NCT02541331Phase 3
Efficacy Of Bacterial Lysate In Asthmatic Children
NCT02417649Phase 4
Advanced Immunological Approach in COPD Exacerbation
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5